Clinical trials: Age Related Maculopathy
AMD, Wet AMD
INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD
The purpose of this study is to confirm the safety and establish the effectiveness of two doses from the IRay System for the treatment of wet AMD.
- Conditions
- AMD, Wet AMD, Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration
- Trial name
- INTREPID (NCT01016873)
- Testing
- IRay
- Where
- 21 sites in Austria, Czechia and 3 more
- Volunteers
- 230 people
- Sponsor
- Oraya Therapeutics, Inc.
Geographic Atrophy
Evolution and Risk Factors Associated With Geographic Atrophy Progression
Age-related macular degeneration is one of the leading causes of blindness worldwide. The factors that induce the progression of geographic atrophy, the advanced form of dry age-related macular degeneration, remain poorly…
- Trial name
- GAIN (NCT01694095)
- Where
- Spain
- Volunteers
- 96 people
- Sponsor
- Institut de la Macula y la Retina
Age-related Macular Degeneration, Vitamin D Deficiency
Omega 3 and Vitamin D Dosage in a Population With Moderate to High Risk of AMD
Objectives: The investigators conducted a prospective study in Belgium with the objective to determine the proportion of subjects identified at moderate-to-high risk for AMD, based on the STARS® questionnaire, in need of…
- Trial name
- OVID-AMD (NCT04482465)
- Testing
- blood sample
- Where
- Belgium
- Volunteers
- 50 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Age-Related Macular Degeneration
Effect of Micronutrient Supplementation on the Intestinal Microbiota in Patients With Age-related Macular Degeneration - The Gut-Retina-axis Study
Age-related macular degeneration (AMD) is a leading cause of visual impairment in the elderly, characterized by multifactorial etiology.
- Trial name
- NCT06391411
- Testing
- a micronutrient mix containing lutein (10 mg), zeaxanthin (2 mg), saffron (20 mg), vitamin C (80 mg), vitamin E (12 mg) and zinc (10mg), anti-VEGF treatment
- Where
- Italy
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Azienda Ospedaliero-Universitaria Careggi
Macular Degeneration
Ranibizumab and Reduced Fluence PDT for AMD
Single agent anti-VEGF therapies such as ranibizumab have shown great promise and have set the standard for visual outcomes in treating wet macular degeneration.
- Trial name
- RAP (NCT00527475)
- Testing
- ranibizumab, verteporfin
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Texas Retina Associates
Age Related Macular Degeneration
Study of WA-NG Telescope Prosthesis in Patients With End-stage Age-related Macular Degeneration
This is a pilot study to evaluate the safety of the Model WA-NG telescope prosthesis in patients with bilateral moderate to profound central vision impairment due to end-stage age-related macular degeneration.
- Trial name
- NCT01361256
- Testing
- Telescope prosthesis, WA-NG Telescope Prothesis
- Where
- Israel
- Sponsor
- VisionCare, Inc.
Age Related Macular Degeneration
Colour Contrast Sensitivity for the Early Detection of Wet Age-related Macular Degereration (CEDAR)
Neovascular or wet age-related macular degeneration (ARMD) is a retinal disease and is the leading cause of sight loss in the over 50s; it constitutes a major public health problem which will have an increasingly large impact as…
- Trial name
- CEDAR (NCT02173496)
- Testing
- Colour Contrast Sensitivity
- Where
- United Kingdom
- Volunteers
- 233 people
- Sponsor
- Aston University
Neovascular Age-Related Macular Degeneration (nAMD)
Real-world Study of Aflibercept 8 mg in nAMD
The goal of this observational study is to explore the effectiveness of aflibercept 8 mg in treating both treatment-naive and previously treated patients with neovascular age-related macular degeneration (nAMD) in a real-world…
- Trial name
- NCT07640997
- Testing
- Aflibercept 8mg
- Where
- 27 sites in China
- Volunteers
- 300 people
- Sponsor
- Peking University People's Hospital
Age-Related Macular Degeneration
Evaluation of Clinical Progression, Prognostic Factors, and Quality of Life in Patients with Age-related Macular Degeneration.
The VERA-AMD study is a prospective, observational study designed to evaluate clinical progression, prognostic factors, and quality of life in patients with age-related macular degeneration (AMD).
- Trial name
- VERA-AMD (NCT06899360)
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- University of Udine
Age-related Macular Degeneration (ARMD)
Switching to Aflibercept 8mg in Patients Showing Limited Response to Previous Treatment
The treatment landscape for neovascular AMD has evolved with various anti-VEGF agents since 2006. Ranibizumab initially led the way, but its limited efficacy in reducing retinal edema paved the way for aflibercept in 2011, which…
- Trial name
- NCT06683950
- Testing
- Aflibercept 8mg
- Where
- South Korea
- Volunteers
- 35 people
- Sponsor
- Kim's Eye Hospital
Neovascular Age-related Macular Degeneration (AMD)
Progression Suppression and Retinal Regression in VEGF-resistant AMD
The goal of this clinical trial is to assess safety and efficacy in patients with Neovascular Age-related Macular Degeneration with no response to existing therapy.
- Trial name
- PRESERVE (NCT07005323)
- Testing
- Pars plana vitrectomy
- Where
- 3 sites in Japan
- Volunteers
- 10 people
- Sponsor
- PharmaBio Corporation
Neovascular Age-related Macular Degeneration
An OCT-Guided Variable Dosing Regimen With Ranibizumab for the Treatment of Neovascular AMD
This study was designed to evaluate a variable dosing regimen with intravitreal ranibizumab for the treatment of patients with neovascular age-related macular degeneration (AMD) in the Prospective OCT Imaging of Patients with…
- Trial name
- NCT00373659
- Testing
- Ranibizumab (Lucentis)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Miami
Macular Degeneration, Maculopathy, Age-Related
An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMD
The purpose of this study is to demonstrate that anecortave acetate is superior to placebo in maintenance of visual acuity at the 12- and 24-month visits.
- Trial name
- NCT00058994
- Testing
- anecortave acetate
- Where
- United States
- Sponsor
- Alcon Research
Age Related Macular Degeneration (ARMD), Retinal Vein Occlusion (RVO)
Comparison of Intravitreal Anti-VEGF Treatment Burden in Different Retinal Diseases
The study compares the perceived treatment burden in patients undergoing intravitreal anti-VEGF treatment for either wet age related macular degeneration, macular edema after retinal vein occlusions or diabetic macular edema.
- Conditions
- Age Related Macular Degeneration (ARMD), Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME)
- Trial name
- NCT07514559
- Where
- Austria
- Volunteers
- 393 people
- Sponsor
- Hospital Hietzing
Neovascular Age-related Macular Degeneration
Combination of Ranibizumab and Verteporfin Therapy in Neovascular Age-related Macular Degeneration
The purpose of this study is to evaluate changes in preferential hyperacuity perimeter (PHP) and fundus autofluorescence (FAF) in patients with neovascular age-related macular degeneration receiving combination of ranibizumab…
- Trial name
- NCT00967213
- Testing
- ranibizumab
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- Novartis Korea Ltd.
Wet Age-Related Macular Degeneration
Evaluation of RC28-E Injection in Wet Age-related Macular Degeneration
This is a non-randomized, open-label, multicenter, 48-week study to investigate the efficacy, safety and pharmacokinetics of RC28-E injection in the treatment of patients with wet age-related macular degeneration by multiple…
- Trial name
- NCT04270669
- Testing
- intravitreal injection of RC28-E 0.5mg, intravitreal injection of RC28-E 1.0mg, intravitreal injection of RC28-E2.0mg
- Where
- China
- Volunteers
- 37 people
- Sponsor
- RemeGen Co., Ltd.
Neovascular Age-related Macular Degeneration
Trial to Evaluate the Safety and Tolerability of Repeated Intravitreal Injection of IBI302 in Neovascular AMD Patients
This study is designed for multi-center, open-label, randomized, dose escalation phase I trial to evaluate the safety and tolerability of a multiple dose intravitreal injection of IBI302 in neovascular AMD patients.
- Trial name
- NCT04370379
- Testing
- IBI302 (the first dose level), IBI302 (the second dose level), Aflibercept
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Visual Impairment, Neovascular Age-related Macular Degeneration (nAMD)
The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema
This is an observational study in which only data are collected from people who have already been prescribed aflibercept 8 mg by their own doctors.
- Conditions
- Visual Impairment, Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macula Edema (DME)
- Trial name
- NCT06075147
- Testing
- Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)
- Where
- 18 sites in Australia, Canada and 16 more
- Volunteers
- 2,500 people
- Sponsor
- Bayer
Neovascular Age Related Macular Degeneration
Safety Study of iSONEP (Sonepcizumab/LT1009) to Treat Neovascular Age-related Macular Degeneration
Age-related macular degeneration (AMD) is a disease that, in time, destroys the macula, which is the central part of the retina that gives sharp central vision.
- Trial name
- NCT00767949
- Testing
- iSONEP
- Where
- 5 sites in United States
- Volunteers
- 15 people
- Sponsor
- Lpath, Inc.
Retinal Degeneration, Age-Related Macular Degeneration
Adaptive Optics Imaging of Outer Retinal Diseases
The objective of the study is to collect adaptive optics (AO) retinal images from human subjects with outer retinal diseases (diseases of the outer retina including photoreceptor, retinal pigment epithelium (RPE), basement…
- Conditions
- Retinal Degeneration, Age-Related Macular Degeneration, Retinitis Pigmentosa, Hydroxychloroquine Retinopathy
- Trial name
- NCT05355415
- Testing
- Adaptive optics imaging
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- Food and Drug Administration (FDA)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.